Journal of Clinical Oncology
Articles in this Issue
Small Cemetery Within
This piece reflects on the unseen emotional burden carried within oncology, where each clinical encounter leaves a lasting imprint beyond measurable outcomes.
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial
PURPOSE Ruxolitinib improves splenomegaly and symptoms in myelofibrosis (MF) but lacks reliable clonal burden reduction. Selinexor, an oral inhibitor of exportin 1, has demonstrate...
Rethinking Cardiovascular Events, End Points, and Surveillance in Oncology Trials
Reply to: “Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation” and “Impact of Transplant Type on Infection Risk in Studies of Neutropenic Diets”
Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment
PURPOSE The optimal second-line strategy for patients with extensive-stage small cell lung cancer (ES-SCLC) developing brain-only progression (BOP) after first-line therapy remains...
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
PURPOSE Revumenib is an oral inhibitor of menin-KMT2A, a key dependency in acute myeloid leukemia (AML) with KMT2A...
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association
The unprecedented expansion of approved oncology therapies has prolonged survival and transformed the prognosis for many patients diagnosed with cancer. However, cancer treatments may be associated wi...
Impact of Transplant Type on Infection Risk in Studies of Neutropenic Diets
Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis
PURPOSE Tamoxifen 20 mg once-daily reduces the risk of breast cancer recurrence after ductal carcinoma in situ (DCIS), but its use is limited by adverse effects. Lower doses may be...
Brain-Only Progression After First-Line Therapy in Extensive-Stage Small Cell Lung Cancer: Treat the Sanctuary, Preserve the Backbone
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the...
Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial
PURPOSE The phase III CHALLENGE trial (CCTG CO.21) demonstrated that a 3-year structured exercise program (SEP) improved disease-free and overall survival versus health education m...
Liberalized Diets During Neutropenia: Ongoing Uncertainty in Hematopoietic Stem-Cell Transplantation
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Mass spectrometry (MS) offers a minimally invasive approach for detecting monoclonal proteins in multiple myeloma (MM), but large prospective evaluations remain limited. We analyzed 3,301 serum sample...
Histotripsy and the IDEAL Framework: A Clarion Call for the Responsible and Evidence-Based Application of New Technology
The evaluation of novel health technologies is increasingly complicated by a landscape of pervasive social media influence and intense product marketing, factors that may distort evidence appraisal an...